Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Biondvax Pharma ADR
(NQ:
BVXV
)
N/A
UNCHANGED
Last Price
Updated: 3:59 PM EDT, Sep 6, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
-
Bid (Size)
1.250 (3)
Ask (Size)
1.380 (2)
Prev. Close
1.360
Today's Range
N/A - N/A
52wk Range
1.300 - 1.370
Shares Outstanding
461,285,824
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
BC Study Uncovers Cause of Four Major Pediatric Allergies
September 07, 2023
Via
Investor Brand Network
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Rebrands as Scinai Immunotherapeutics Ltd.
September 06, 2023
Via
Investor Brand Network
Performance
More News
Read More
BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel Inflammation and Immunology (I&I) Biological Therapeutics
September 06, 2023
From
BiondVax Pharmaceuticals Ltd.
Via
GlobeNewswire
BioMedNewsBreaks — BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Positioned Favorably with Worldwide License to Anti-IL-17 NanoAbs
September 01, 2023
Via
Investor Brand Network
Exposures
Product Safety
Malaria Case Prompts Army to Ask Infectious Disease Experts to Analyze Mosquitoes
August 31, 2023
Via
Investor Brand Network
England Sees Soaring Numbers of Hospitalizations for Severe Allergies
August 28, 2023
Via
Investor Brand Network
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Is Fast on the Trail to Target IL-17
August 25, 2023
Via
Investor Brand Network
How Allergy Sufferers Can Benefit from Immunotherapy
August 22, 2023
Via
Investor Brand Network
Analyzing Link Between Hormonal Contraceptives, Autoimmunity
August 18, 2023
Via
Investor Brand Network
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Advances NanoAb Therapy as IL-17 Drug Candidate for Psoriasis Treatment
August 18, 2023
Via
Investor Brand Network
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Q2 Financial Report, Corporate Update
August 16, 2023
Via
Investor Brand Network
Stem Cell Transplants Followed by Immunotherapy Show Efficacy Against Pediatric Nerve Tumors
August 15, 2023
Via
Investor Brand Network
BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) Alpaca-Derived Nanobodies for Potential Treatment of Diseases Underserved by Current Therapeutics
August 14, 2023
Via
Investor Brand Network
Exposures
COVID-19
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Q2 Financial Report, Corporate Update
August 11, 2023
Via
Investor Brand Network
Exposures
COVID-19
BiondVax Reports Second Quarter Financial Results and Provides Business Update
August 11, 2023
From
BiondVax Pharmaceuticals Ltd.
Via
GlobeNewswire
How Immunotherapy Outcomes Can Be Affected by Diet, Gut Microbiota
August 09, 2023
Via
Investor Brand Network
Study Finds Link Between Food Allergies in Infants, Childhood Asthma Onset
August 03, 2023
Via
Investor Brand Network
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Granted Extension to Regain NASDAQ Compliance
August 02, 2023
Via
Investor Brand Network
Exposures
COVID-19
Nasdaq Grants BiondVax Extension to Regain Compliance with Listing Rules
August 01, 2023
From
BiondVax Pharmaceuticals Ltd.
Via
GlobeNewswire
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Leveraging Unique NanoAb Pipeline to Target Large, Growing Markets
July 28, 2023
Via
Investor Brand Network
Review Shows AI Could Be Pivotal in Infectious Disease Prevention
July 28, 2023
Via
Investor Brand Network
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
COVID-19
M&A Activity, Booming Sales of Anti-IL-17 Drugs Suggest Strong Upside Potential for BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV)
July 26, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) CDMO Services Designed to Meet Needs of Pharmaceutical, Biotechnology Companies of All Sizes
July 24, 2023
Via
Investor Brand Network
Exposures
COVID-19
Psoriasis Could Be Behind Frequent Fatigue
July 24, 2023
Via
Investor Brand Network
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) CEO Amir Reichman Featured on IBN’s The Bell2Bell Podcast
July 19, 2023
Via
Investor Brand Network
Exposures
COVID-19
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.